SciELO - Scientific Electronic Library Online

 
vol.8 número1Associated comorbidities of patients with Rheumatoid Arthritis in external consulationImmunomodulatory activity of species of the genus Baccharis índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Paraguaya de Reumatología

versão On-line ISSN 2413-4341

Resumo

MARTINEZ, Cynthia Gisela Holt et al. Frequencies of adverse events following COVID-19 vaccination in patients with Systemic Lupus Erythematosus Erythematosus in a referral center in Asuncion-Paraguay. Rev. parag. reumatol. [online]. 2022, vol.8, n.1, pp.41-44. ISSN 2413-4341.  https://doi.org/10.18004/rpr/2022.08.01.41.

The aim of this study is to determine the frequency of adverse events of COVID-19 vaccination in patients with SLE who are attended at referral medical centers in Paraguay. This is an observational, cross-sectional, descriptive study. Fifty-two patients with SLE who received at least one dose of anticovid vaccine were included. Of which 100% received the first dose, 92.3% the second dose and 15.38% the third dose; 44.6% received SputnikV; 16% Moderna; 12.5% Pfizer, 7.1% AstraZeneca, 3.6% Covaxin and 2.1% Hayat Vax, 8 patients received their third dose corresponding to 3 from Pfizer, 3 from Moderna, 2 from AstraZeneca. In the 108 doses applied, a total of 43 adverse events were recorded, 95.3% within the first 5 days and the rest at 5 days. A total of 51.2% presented the adverse event after the first dose, 39.5% after the second dose and 9.3% after the third dose. The mean duration of symptoms was 2.3 days ±1.4. The most important adverse effect was pain at the injection site, followed by fever and fatigue. Exacerbation of SLE was also recorded as an adverse event in 8.3%. Mild adverse effects were recorded, it is concluded that vaccination against covid 19 is safe for patients with SLE.

Palavras-chave : adverse events; vaccine; COVID-19; Lupus.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )